Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
CC transcript
Quarterly results
Credit agrmnt [a]
Director departure
|
|
Pediatrix Medical Group, Inc. (MD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Quarterly results|
Docs:
|
"Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 3, 2023 - Pediatrix Medical Group, Inc. , the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.34 per share for the three months ended June 30, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.39. For the 2023 second quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $501 million; • Income from continuing operations of $28 million; and • Adjusted EBITDA of $59 million. “Our second quarter operating results were in line with our expectations and reflect stable patient volumes and strong cash gene..." |
|
| 05/11/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Pediatrix Medical Group Reports First Quarter Results FORT LAUDERDALE, Fla., May 2, 2023 - Pediatrix Medical Group, Inc. , the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.17 per share for the three months ended March 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.23. For the 2023 first quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $491 million; • Income from continuing operations of $14 million; and • Adjusted EBITDA of $40 million. “Our first quarter operating results were in line with our expectations and reflected modest improvements in revenue cycle managemen..." |
|
| 03/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/16/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/04/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
8-K
| Quarterly results|
Docs:
|
"Mednax Reports First Quarter Results FORT LAUDERDALE, Fla., April 28, 2022 - Mednax, Inc. , whose affiliated practices operate as Pediatrix® Medical Group, the nation’s leading provider of highly specialized health care for women, children and babies, today reported a loss from continuing operations of $0.25 per share for the three months ended March 31, 2022. Results from continuing operations include a pretax loss on early extinguishment of debt of $57 million. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.33. For the 2022 first quarter, Mednax reported the following results from continuing operations: • Net revenue of $482 million; • Loss from continuing operations of $21 million; and • Adjusted EBITDA of $51 million. “Our..." |
|
| 02/25/2022 |
8-K
| Quarterly results |
| 02/17/2022 |
8-K
| Quarterly results|
Docs:
|
"Mednax Reports Fourth Quarter Results FORT LAUDERDALE, Fla., February 17, 2022 - Mednax, Inc. , and its affiliated practices operating as Pediatrix® Medical Group, the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.47 per share for the three months ended December 31, 2021. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.52. For the 2021 fourth quarter, Mednax reported the following results from continuing operations: • Net revenue of $499 million; • Income from continuing operations of $68 million; and • Adjusted EBITDA of $81 million. “Our fourth quarter results mark the end of a solid year, thanks to our focus on women’s, new..." |
|
| 02/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/19/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/28/2021 |
8-K
| Quarterly results |
| 08/27/2021 |
8-K
| Quarterly results |
| 08/06/2021 |
8-K
| Quarterly results |
| 05/17/2021 |
8-K
| Quarterly results |
| 05/14/2021 |
8-K
| Quarterly results |
| 05/07/2021 |
8-K
| Quarterly results |
| 02/18/2021 |
8-K
| Quarterly results |
| 12/21/2020 |
8-K
| Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligati... |
| 11/24/2020 |
8-K
| Other Events Interactive Data |
| 11/06/2020 |
8-K
| Quarterly results |
| 09/29/2020 |
8-K
| Quarterly results |
| 08/25/2020 |
8-K
| Quarterly results |
| 07/30/2020 |
8-K
| Quarterly results |
| 07/13/2020 |
8-K
| Quarterly results |
| 06/05/2020 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/12/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 05/06/2020 |
8-K
| Quarterly results |
|
|
|